Pine

This is the most consistent finding for pine bark extract. In a double-blind RCT, 40 patients with chronic venous insufficiency and leg varices took Pycnogenol 100 mg three times daily or placebo for two months; the extract significantly reduced subcutaneous oedema, leg heaviness and pain, with roughly 60% of treated patients losing oedema entirely, while placebo did nothing ^{8Reference 8Arcangeli P · 2000RCTPycnogenol in chronic venous insufficiency — randomised placebo-controlledView study →}. A dedicated review collates further trials in CVI, long-haul-flight leg oedema, venous ulcers and haemorrhoids, attributing the effect to the extract’s antioxidant, anti-inflammatory, vasodilator and collagen-stabilising actions ^{9Reference 9Gulati OP · 2014ReviewPycnogenol® in chronic venous insufficiency and related venous disorders — reviewView study →}. The 2020 Cochrane review found oedema among the outcomes where pine bark extract showed benefit, though it graded overall certainty low because trials were small and mostly funded by manufacturers ^{1Reference 1Robertson NU et al. · 2020Systematic reviewPine bark (Pinus spp.) extract for treating chronic disorders — systematic reviewView study →}. The active fraction is the bark’s proanthocyanidin OPCs — this is not an effect of needle tea or resin.

Gap: Trials are small, short, and predominantly industry-sponsored; no large independent RCT and no head-to-head against standard compression or venotonics of comparable rigour.

Several meta-analyses converge on a modest antihypertensive effect for pine bark extract. A 2019 meta-analysis of 24 RCTs (1,594 participants) found reductions in systolic (−2.5 mmHg) and diastolic (−1.8 mmHg) blood pressure alongside lower fasting glucose, HbA1c and BMI ^{2Reference 2Malekahmadi M et al. · 2019Meta-analysisEffects of pycnogenol on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials — meta-analysisView study →}; a 2025 meta-analysis of 27 RCTs (1,685 participants) reported similar systolic (−2.3 mmHg) and diastolic (−2.6 mmHg) reductions plus small drops in fasting glucose, HbA1c, body weight and LDL ^{3Reference 3Mohammadi S et al. · 2025Meta-analysisDoes supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis — meta-analysisView study →}. A blood-pressure-specific meta of 12 trials confirmed the direction of effect, more pronounced with longer supplementation ^{4Reference 4Pourmasoumi M et al. · 2020Meta-analysisEffect of pycnogenol supplementation on blood pressure: A systematic review and meta-analysis of clinical trials — meta-analysisView study →}. Honesty requires noting the counter-evidence: a PRISMA-compliant meta restricted to seven double-blind placebo-controlled trials found no significant blood-pressure change ^{5Reference 5Fogacci F et al. · 2020Meta-analysisEffect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies — meta-analysisView study →}, and lipid meta-analyses were largely null apart from a small rise in HDL ^{6,7Reference 6Sahebkar A · 2014Meta-analysisA systematic review and meta-analysis of the effects of pycnogenol on plasma lipids — meta-analysisView study →Reference 7Hadi A et al. · 2019Meta-analysisThe impact of pycnogenol supplementation on plasma lipids in humans: A systematic review and meta-analysis of clinical trials — meta-analysisView study →}. The effect is real but small, and best read as a cardiometabolic nudge rather than a treatment.

Gap: Effect sizes are clinically minor, heterogeneity is high, and the null high-quality meta-analysis ^{5Reference 5Fogacci F et al. · 2020Meta-analysisEffect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies — meta-analysisView study →} shows how sensitive the signal is to trial selection.

Antioxidant capacity is the mechanistic backbone of the whole genus, and the one place the different pine parts genuinely converge — the bark’s proanthocyanidins, the needles’ proanthocyanidins and flavonoids, and the pollen’s phenolics all scavenge free radicals in assay after assay ^{26,32Reference 26Park YS et al. · 2011In vitroAntioxidant activity and analysis of proanthocyanidins from pine (Pinus densiflora) needles — in vitroView study →Reference 32Lee KH et al. · 2009In vitroAntioxidant and antiinflammatory activity of pine pollen extract in vitro — in vitroView study →}. For pine needles, though, the human-facing evidence is thin and the chemistry is frequently mis-sourced: the often-quoted essential-oil profile (α-terpineol ~30%, linalool ~24%) and its radical-scavenging data come from Cedrus deodara, a cedar, not a Pinus [22 — see Gap]. Genuine Pinus densiflora needle extracts do show DPPH scavenging and cellular ROS reduction in vitro ^{26Reference 26Park YS et al. · 2011In vitroAntioxidant activity and analysis of proanthocyanidins from pine (Pinus densiflora) needles — in vitroView study →}, and P. densiflora needle extract was antioxidant, antimutagenic and antitumour in cell and rodent assays ^{27Reference 27Kwak CS et al. · 2006AnimalAntioxidant, antimutagenic, and antitumor effects of pine needles (Pinus densiflora) — animal modelView study →}. Human oxidative-stress biomarker improvements are documented mainly for the standardised bark extract, whose clinical and molecular effects on skin — including protection against UV-induced damage and improved skin barrier and elasticity — are the most developed human-facing antioxidant application in the genus ^{1,25Reference 1Robertson NU et al. · 2020Systematic reviewPine bark (Pinus spp.) extract for treating chronic disorders — systematic reviewView study →Reference 25Grether-Beck S et al. · 2016ReviewFrench Maritime Pine Bark Extract (Pycnogenol®) Effects on Human Skin: Clinical and Molecular Evidence — reviewView study →}. Needle polysaccharide fractions from Pinus massoniana also raised antioxidant-enzyme activity and lowered lipids in high-fat-fed mice ^{28Reference 28Chu L et al. · 2019AnimalChemical composition, antioxidant activities of polysaccharide from Pine needle (Pinus massoniana) and hypolipidemic effect in high-fat diet-induced mice — mouseView study →}.

Gap: Direct human antioxidant-outcome data exist essentially only for the bark extract; the widely cited needle-oil antioxidant figures actually describe Cedrus deodara (Himalayan cedar), not pine, and should not be attributed to the genus.

Pine bark extract has repeatable, if modest, glucose-lowering data. A double-blind placebo-controlled RCT in 77 type 2 diabetics found that 100 mg Pycnogenol daily for 12 weeks, on top of standard therapy, significantly lowered plasma glucose and HbA1c versus placebo ^{12Reference 12Liu X et al. · 2004RCTAntidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II — randomised placebo-controlledView study →}. A later RCT in type 2 diabetics with microalbuminuria reported improved metabolic status and lower vascular cell adhesion molecule-1 ^{13Reference 13Navval-Esfahlan E et al. · 2021RCTEffect of French maritime pine bark extract supplementation on metabolic status and serum vascular cell adhesion molecule-1 levels in patients with type 2 diabetes and microalbuminuria — randomised controlled trialView study →}, and the cardiometabolic meta-analyses above found pooled reductions in fasting glucose and HbA1c ^{2,3Reference 2Malekahmadi M et al. · 2019Meta-analysisEffects of pycnogenol on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials — meta-analysisView study →Reference 3Mohammadi S et al. · 2025Meta-analysisDoes supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis — meta-analysisView study →}. Mechanistically, pine bark and needle extracts inhibit α-glucosidase and α-amylase, blunting postprandial glucose in diabetic mice ^{14Reference 14Kim YM et al. · 2005In vitroInhibitory effect of pine extract on alpha-glucosidase activity and postprandial hyperglycemia — in vitroView study →}. As throughout, this is bark-extract data — not needle tea.

Gap: Trials are short (≤12 weeks) and add-on to existing therapy; no evidence on hard endpoints or as monotherapy, and the needle/whole-herb forms have no human glycaemic data.

Pine’s anti-inflammatory activity is mechanistically well mapped but clinically shallow. The bark extract inhibits NF-κB signalling and downstream COX-2 and 5-lipoxygenase, lowering leukotrienes — the rationale behind its use as an add-on in asthma ^{24Reference 24Belcaro G et al. · 2011ReviewPycnogenol® improvements in asthma management — reviewView study →}. In a randomised, double-blind, placebo-controlled crossover trial, Pycnogenol improved asthma symptoms and lung function versus placebo ^{23Reference 23Hosseini S et al. · 2001RCTPycnogenol((R)) in the Management of Asthma — randomised placebo-controlledView study →}. In animal gout models, Pycnogenol attenuated urate-crystal-induced COX-2, IL-8 and iNOS in joint tissue ^{22Reference 22Peng YJ et al. · 2012AnimalPycnogenol attenuates the inflammatory and nitrosative stress on joint inflammation induced by urate crystals — animal modelView study →}. The needle essential oil is credited with COX-2 inhibition, but that specific data traces to Cedrus deodara rather than a true pine.

Gap: Human anti-inflammatory evidence is limited to a small asthma crossover trial and registry work; the joint/gout data are animal-only, and the needle-oil enzyme claims are mis-attributed to a cedar.

Pine bark extract has a niche but genuine ophthalmic signal in early diabetic microangiopathy. A randomised controlled trial found Pycnogenol improved retinal microcirculation, reduced retinal oedema and improved visual acuity in early diabetic retinopathy, plausibly by increasing capillary resistance and reducing leakage ^{10Reference 10Steigerwalt R et al. · 2009RCTPycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy — randomised controlled trialView study →}. A review of five clinical trials (≈1,289 patients, several from the 1960s–80s) reported slowed progression of retinopathy ^{11Reference 11Schönlau F · 2001ReviewPycnogenol for diabetic retinopathyView study →}. The mechanism is consistent with the extract’s vasoprotective and capillary-sealing actions seen in venous disease.

Gap: The supporting trials are old, small and heterogeneous, several predating modern retinopathy management; this is adjunctive at best and not a substitute for standard ophthalmic care.

The erectile-function evidence is real but confounded, because pine bark extract is almost always tested combined with L-arginine. A 2023 meta-analysis of three trials (184 men) found the Pycnogenol-plus-L-arginine combination significantly improved erectile-function, satisfaction and desire scores versus control ^{15Reference 15Tian Y et al. · 2023Meta-analysisEfficacy of L-arginine and Pycnogenol® in the treatment of male erectile dysfunction: a systematic review and meta-analysis — meta-analysisView study →}; earlier open and controlled studies reported the same ^{16,17Reference 16Stanislavov R · 2003Clinical trialTreatment of erectile dysfunction with pycnogenol and L-arginine — clinical trialView study →Reference 17Trebaticky B et al. · 2019RCTNatural polyphenols improve erectile function and lipid profile in patients suffering from erectile dysfunction — randomised controlled trialView study →}, the rationale being that arginine supplies substrate and the extract upregulates nitric-oxide synthase to relax cavernous smooth muscle ^{16Reference 16Stanislavov R · 2003Clinical trialTreatment of erectile dysfunction with pycnogenol and L-arginine — clinical trialView study →}. Because arginine alone raises nitric oxide, the pine-specific contribution can’t be isolated from these designs.

Gap: Almost no trial tests pine bark extract alone for ED — the effect is inseparable from co-administered L-arginine, and testosterone was not improved ^{15Reference 15Tian Y et al. · 2023Meta-analysisEfficacy of L-arginine and Pycnogenol® in the treatment of male erectile dysfunction: a systematic review and meta-analysis — meta-analysisView study →}.

Pine bark extract shows a plausible but methodologically soft cognitive signal. An 8-week study in students reported improved attention, memory, executive function and exam performance with Pycnogenol ^{18Reference 18Luzzi R et al. · 2011Clinical trialPycnogenol® supplementation improves cognitive function, attention and mental performance in students — clinical trialView study →}, and a 12-week registry study in professionals with elevated oxidative stress reported similar gains ^{19Reference 19Belcaro G et al. · 2014Clinical trialPycnogenol® improves cognitive function, attention, mental performance and specific professional skills in healthy professionals aged 35-55 — clinical trialView study →}. In ADHD, a network meta-analysis of antioxidant therapies ranked pycnogenol among the more effective agents on parent- and teacher-rated attention and hyperactivity scales, though within a very heterogeneous evidence base ^{20Reference 20Zhou P et al. · 2024Meta-analysisSafety and efficacy of antioxidant therapy in children and adolescents with attention deficit hyperactivity disorder: A systematic review and network meta-analysis — systematic reviewView study →}. The proposed mechanism is again vascular and antioxidant — improved cerebral microperfusion and reduced oxidative stress.

Gap: Most cognition studies are registry or product-evaluation designs rather than blinded placebo-controlled RCTs, raising expectation and selection bias; the ADHD signal comes from indirect network comparisons.

The joint evidence is suggestive but low-quality. A large systematic review and meta-analysis of dietary supplements for osteoarthritis included pine bark extract among agents with short-term effects on pain and function, but graded the overall certainty very low and cautioned against over-reading small trials ^{21Reference 21Liu X et al. · 2018Meta-analysisDietary supplements for treating osteoarthritis: a systematic review and meta-analysis — meta-analysisView study →}. Mechanistic support comes from a gout model where Pycnogenol reduced urate-crystal-induced joint inflammation and nitrosative stress ^{22Reference 22Peng YJ et al. · 2012AnimalPycnogenol attenuates the inflammatory and nitrosative stress on joint inflammation induced by urate crystals — animal modelView study →}. There is a coherent anti-inflammatory rationale but sparse, small human data.

Gap: Human OA trials are few, small and low-certainty; no adequately powered independent RCT confirms a clinically meaningful benefit.

Pine’s antimicrobial reputation — resin as a wound sealant, needle infusions as washes — is well grounded in vitro but untested in humans. Essential oils from coniferous Pinus species (P. densiflora, P. koraiensis) show antibacterial and antifungal activity ^{29Reference 29Hong EJ et al. · 2004In vitroAntibacterial and antifungal effects of essential oils from coniferous trees — in vitroView study →}, and P. sylvestris needle oil had bactericidal and anti-biofilm activity against Neisseria gonorrhoeae and Streptococcus suis ^{30Reference 30Jurado P et al. · 2023In vitroEssential oils of Pinus sylvestris, Citrus limon and Origanum vulgare exhibit high bactericidal and anti-biofilm activities against Neisseria gonorrhoeae and Streptococcus suis — in vitroView study →}. P. nigra needle oil, rich in α-pinene and β-pinene, was likewise antimicrobial ^{31Reference 31Politeo O et al. · 2011In vitroChemical composition and antimicrobial activity of the essential oil of endemic Dalmatian black pine (Pinus nigra ssp. dalmatica) — in vitroView study →}. These are genuine Pinus data (unlike the mis-sourced antioxidant figures), but all are laboratory assays.

Gap: No controlled human trials of pine resin or needle preparations for infection or wound healing; efficacy is inferred entirely from in vitro potency at concentrations topical use may not reach.

The pollen’s traditional “longevity tonic” role has a modest preclinical footprint. Pine pollen extract delayed replicative senescence in human diploid fibroblasts and reduced markers of accelerated aging in D-galactose-treated mice, improving antioxidant enzyme activity ^{33Reference 33Mao GX et al. · 2012AnimalAntiaging effect of pine pollen in human diploid fibroblasts and in a mouse model induced by D-galactose — mouseView study →}. Pollen extract also showed direct antioxidant and anti-inflammatory activity in vitro ^{32Reference 32Lee KH et al. · 2009In vitroAntioxidant and antiinflammatory activity of pine pollen extract in vitro — in vitroView study →}, and a bibliometric review catalogues a broad but largely preclinical Chinese-medicine literature on the pollen ^{34Reference 34Liang SB et al. · 2020ReviewThe Potential Effects and Use of Chinese Herbal Medicine Pine Pollen (Pinus pollen): A Bibliometric Analysis of Pharmacological and Clinical Studies — reviewView study →}. This is a coherent antioxidant-based anti-aging hypothesis with no human evidence.

Gap: The entire signal is cell and rodent work — chiefly one accelerated-aging mouse model — with no clinical trial of pine pollen for aging or longevity in humans.

The claim that pine pollen “boosts testosterone” does not survive the numbers. Pollen of Scots pine (Pinus sylvestris) genuinely contains testosterone, epitestosterone and androstenedione — first shown in 1971 ^{35Reference 35Saden-Krehula M et al. · 1971In vitroTestosterone, epitestosterone and androstenedione in the pollen of Scotch pine P. silvestris L — in vitroView study →} — but at nanogram-per-gram levels: on the order of ~80 ng/g testosterone, meaning a large pollen dose delivers well under a microgram, orders of magnitude below any physiologically active oral amount. Any real-world benefit for male vitality is far more plausibly nutritional and anti-inflammatory than hormonal, and there are no human trials showing pollen raises serum testosterone. It is not an anabolic agent and should not be presented as one.

Gap: No human trial demonstrates any change in serum androgens or clinical hypogonadism outcomes from pine pollen; the androgen content is real but pharmacologically negligible.

Standardised pine bark extract (Pycnogenol/Oligopin) has a good tolerability record across dozens of RCTs, with adverse events generally mild and comparable to placebo ^{1Reference 1Robertson NU et al. · 2020Systematic reviewPine bark (Pinus spp.) extract for treating chronic disorders — systematic reviewView study →}. The main real-world cautions concern the other parts of the tree rather than the bark: pine pollen, long thought hypoallergenic, can cause genuine IgE-mediated allergy and cross-reacts with other conifer and grass pollens, so first-time users should patch/skin test ^{36Reference 36Gastaminza G et al. · 2009ObservationalAllergenicity and cross-reactivity of pine pollen — observationalView study →}. Pine resin tinctures can irritate the gastrointestinal tract and should be dosed low and built up gradually. The needles of some species — notably ponderosa pine (Pinus ponderosa) — contain the abortifacient diterpene isocupressic acid, well documented to cause late-term abortion in cattle ^{37Reference 37James LF et al. · 1989AnimalPine needle abortion in cattle: a review and report of 1973-1984 research — animal modelView study →}; and pine nuts can trigger “pine mouth,” a transient metallic taste disturbance lasting days to weeks ^{38Reference 38Hampton R et al. · 2011ReviewPine mouth — reviewView study →}. Because pine bark extract enhances nitric-oxide-mediated vasodilation and is often combined with blood-pressure and glucose-lowering agents, monitor for additive effects ^{2,12Reference 2Malekahmadi M et al. · 2019Meta-analysisEffects of pycnogenol on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials — meta-analysisView study →Reference 12Liu X et al. · 2004RCTAntidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II — randomised placebo-controlledView study →}. No dedicated human drug-interaction or CYP450 study of pine was identified, so interaction potential is inferred from its pharmacology rather than measured. Do not confuse pine with the toxic yew (Taxus), which has flat needles and red berries.